Market Cap: $240.38B
AI
Amgen Inc.
AMGN
NASDAQ (NASDAQ Global Select)USD
Market Cap: $240.38B
Amgen Inc. ( AMGN ) is making significant strides in the biotechnology sector, particularly in oncology and cardiometabolic health. The company's innovative approaches, notably through the VESALIUS-CV…
Amgen Inc. is making significant strides in crucial therapeutic areas, focusing particularly on oncology and cardiometabolic health. The company's commitment to innovation through key trials and drug…
Amgen Inc. AMGN has recently made significant strides in transforming cardiovascular treatment, particularly for high-risk diabetic patients. With the results of the VESALIUS-CV trial underscoring the…
Amgen Inc. AMGN is navigating a dynamic biotechnology landscape, showcasing significant growth strategies through innovative treatments and key investments. With a robust lineup of therapies addressin…
Amgen (Ticker: AMGN) announces pivotal results from their VESALIUS-CV Phase 3 clinical trial for Repatha, focusing on high-risk diabetic patients and exhibiting a significant reduction in major cardio…
Amgen (Ticker: AMGN) recently showcases groundbreaking results from the Phase 3 VESALIUS-CV subgroup study, shedding light on the benefits of Repatha® for patients grappling with high-risk diabetes. P…
Amgen (Ticker: AMGN) focuses on innovations in cardiometabolic care with recent advancements highlighting its commitment to improving patient outcomes. At the American Diabetes Association's 86th Scie…
Amgen (Ticker: AMGN), a leading biotechnology firm, recently achieves a significant milestone by securing marketing authorization from the European Commission for its drug IMDYLLTRA® (tarlatamab), des…
Amgen Inc (Ticker: AMGN) announces a substantial manufacturing investment strategy focusing on enhancing its biologics production capabilities. In May 2026, Amgen confirms its commitment of $300 milli…
Tavneos' Role in Transforming ANCA-Associated Vasculitis Treatment Amgen navigates a promising path with its innovative therapy Tavneos, specifically approved to treat adults with severe active ANCA-a…
Repatha® Demonstrates Significant Cardiovascular Benefits for High-Risk Diabetes Patients Amgen's recent announcement regarding Repatha® (evolocumab), a groundbreaking PCSK9 inhibitor, marks a signifi…
Amgen Faces Rising Pressure for Affordable Drug Solutions Amidst Industrywide Challenges Amgen, as a leading player in the biotechnology sector, stands at a critical juncture as discussions about pres…
Transforming Drug Affordability: The Emergence of TrumpRx As the pharmaceutical industry grapples with a crisis of affordability, significant innovations are emerging aimed at reducing the financial b…
Amgen Sets to Revolutionize Pharmaceutical Accessibility with Expanded Discount Offerings Amgen announces a significant strategic expansion of its prescription medication offerings, increasing the num…
AMGEN Expands Prescription Offerings to Enhance Healthcare Accessibility Amgen is set to significantly expand its prescription medication offerings, increasing the number of discounted options availab…
Amgen Partners with TrumpRx Initiative to Lower Drug Prices In a decisive move under the TrumpRx initiative, Amgen takes a significant step to lower prescription drug costs, aligning with government g…
Amgen's Role in the TrumpRx Initiative: A Shift Towards Affordable Healthcare Amgen, a leading player in the biopharmaceutical sector, positions itself at the forefront of the TrumpRx initiative, whic…
Amgen's Diverse Analyst Coverage Reflects Complexity in Biotech Landscape Amgen, a leading biotechnology firm, experiences a significant level of scrutiny from financial analysts, with 15 experts weig…
Innovative Adaptations in Biotech: Amgen’s Role in the AI Era In recent discussions surrounding notable biotech stocks, Amgen (NASDAQ: AMGN) finds itself at a critical juncture as the industry increas…
Amgen's Role in the Biotech Revolution: Embracing AI Innovation In the dynamic landscape of biotechnology, Amgen stands out not only for its innovative therapies but also for its ability to adapt to e…
Amgen Gears Up for the Leerink Partners Global Healthcare Conference Amgen, a prominent player in the biotechnology realm, prepares to showcase its latest advancements at the forthcoming Leerink Partn…
Innovation at the Core: Amgen's Continued Commitment to Biotech Leadership In a landscape defined by rapid advancements in biotechnology, Amgen stands as a cornerstone of innovation, continuously resh…
Amgen's Insider Transaction Sparks Investor Inquiry Amgen, a leader in the biopharmaceutical sector, finds itself in the spotlight following a recent insider transaction involving Esteban Santos, the…
### Insider Sale Raises Questions About Strategic Direction at Amgen Amgen's recent insider sale by Executive Vice President Esteban Santos, who offloaded 13,182 shares for approximately $2.7 million,…
Insightful Insider Sale Signals Strategic Direction at Amgen In a significant development for Amgen, Esteban Santos, the Executive Vice President, conducts a noteworthy insider sale of 13,182 shares,…